PHAXIAM Therapeutics (XPAR:PHXM) OCF Yield %: 0.00 (As of Jun. 26, 2026)


XPAR:PHXM PHAXIAM Therapeutics SA XPAR:PHXM
38 GF Score
Price €0.10
View Full Analysis

What is PHAXIAM Therapeutics OCF Yield %?

PHAXIAM Therapeutics XPAR:PHXM 38 OCF Yield % is 0.00 as of Jun. 26, 2026. GuruFocus rates XPAR:PHXM with a GF Score™ of 38/100.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, PHAXIAM Therapeutics's Trailing 12-Month Cash Flow from Operations is €0.00 Mil, and Market Cap is €1.01 Mil. Therefore, PHAXIAM Therapeutics's OCF Yield % for today is 0.00%.

The historical rank and industry rank for PHAXIAM Therapeutics's OCF Yield % or its related term are showing as below:


XPAR:PHXM's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.48
* Ranked among companies with meaningful OCF Yield % only.

PHAXIAM Therapeutics's OCF Margin % for the quarter that ended in Sep. 2023 was %.

PHAXIAM Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

PHAXIAM Therapeutics OCF Yield % Related Terms

PHAXIAM Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics OCF Yield % Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.68 -36.03 -36.27 -86.33 -279.19

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:PHXM
38GF Score
PHAXIAM Therapeutics SA XPAR:PHXM
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

PHAXIAM Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-31.764 / 11.377246076
=-279.19%

PHAXIAM Therapeutics's annualized OCF Yield % for the quarter that ended in Sep. 2023 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=0 * 4 / 29.737343118
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
PHAXIAM Therapeutics (XPAR:PHXM) has a OCF Yield % of 0.00 as of Jun. 26, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' OCF Yield % too high?
PHAXIAM Therapeutics' current OCF Yield % is 0.00. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' OCF Yield % compare to VRTX and REGN?
PHAXIAM Therapeutics' OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (XPAR:PHXM) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For PHAXIAM Therapeutics (XPAR:PHXM), the current OCF Yield % is 0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for XPAR:PHXM

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price